Intramyocardial injection of autologous bone marrow
CA 2487410 C · Owner: Biomet Biologics, Llc · Inventors: Kornowski, Ran; Carpenter, Kenneth W.; Leon, Martin B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are provided for enhancing transfection efficiency of bone marrow cells by transfecting early attaching cells derived from bone marrow in culture. Methods are also provided for utilizing such early attaching cells derived from autologous bone marrow to deliver angiogenesis-promoting transgenes to a patient. The transfected early attaching cells are introduced into an ischemic tissue, such as the heart to enhance formation of collateral , blood vessels. Methods are also provided for treating ischemic muscle by coadministration of autologous bone marrow cells and RGTA for example RGTA11.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 2003 and granted March 24, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.